Search Journal-type in search term and press enter
Southwest Pulmonary and Critical Care Fellowships

Pulmonary Journal Club

(Click on title to be directed to posting, most recent listed first)

May 2017 Phoenix Pulmonary/Critical Care Journal Club
October 2015 Phoenix Pulmonary Journal Club: Lung Volume Reduction
September 2015 Tucson Pulmonary Journal Club: Genomic Classifier
   for Lung Cancer
April 2015 Phoenix Pulmonary Journal Club: Endo-Bronchial Ultrasound in
   Diagnosing Tuberculosis
February 2015 Tucson Pulmonary Journal Club: Fibrinolysis for PE
January 2015 Tucson Pulmonary Journal Club: Withdrawal of Inhaled
    Glucocorticoids in COPD
January 2015 Phoenix Pulmonary Journal Club: Noninvasive Ventilation In 
   Acute Respiratory Failure
September 2014 Tucson Pulmonary Journal Club: PANTHEON Study
June 2014 Tucson Pulmonary Journal Club: Pirfenidone in Idiopathic
   Pulmonary Fibrosis
September 2014 Phoenix Pulmonary Journal Club: Inhaled Antibiotics
August 2014 Phoenix Pulmonary Journal Club: The Use of Macrolide
   Antibiotics in Chronic Respiratory Disease
June 2014 Phoenix Pulmonary Journal Club: New Therapies for IPF
   and EBUS in Sarcoidosis
March 2014 Phoenix Pulmonary Journal Club: Palliative Care
February 2014 Phoenix Pulmonary Journal Club: Smoking Cessation
January 2014 Pulmonary Journal Club: Interventional Guidelines
December 2013 Tucson Pulmonary Journal Club: Hypothermia
December 2013 Phoenix Pulmonary Journal Club: Lung Cancer
   Screening
November 2013 Tucson Pulmonary Journal Club: Macitentan
November 2013 Phoenix Pulmonary Journal Club: Pleural Catheter
   Infection
October 2013 Tucson Pulmonary Journal Club: Tiotropium Respimat 
October 2013 Pulmonary Journal Club: Pulmonary Artery
   Hypertension
September 2013 Pulmonary Journal Club: Riociguat; Pay the Doctor
August 2013 Pulmonary Journal Club: Pneumococcal Vaccine
   Déjà Vu
July 2013 Pulmonary Journal Club
June 2013 Pulmonary Journal Club
May 2013 Pulmonary Journal Club
March 2013 Pulmonary Journal Club
February 2013 Pulmonary Journal Club
January 2013 Pulmonary Journal Club
December 2012 Pulmonary Journal Club
November 2012 Pulmonary Journal Club
October 2012 Pulmonary Journal Club
September 2012 Pulmonary Journal Club
August 2012 Pulmonary Journal Club
June 2012 Pulmonary Journal Club
June 2012 Pulmonary Journal Club
May 2012 Pulmonary Journal Club
April 2012 Pulmonary Journal Club
March 2012 Pulmonary Journal Club
February 2012 Pulmonary Journal Club
January 2012 Pulmonary Journal Club
December 2011 Pulmonary/Sleep Journal Club
October, 2011 Pulmonary Journal Club
September, 2011 Pulmonary Journal Club
August, 2011 Pulmonary Journal Club
July 2011 Pulmonary Journal Club
May, 2011 Pulmonary Journal Club
April, 2011 Pulmonary Journal Club
February 2011 Pulmonary Journal Club 
January 2011 Pulmonary Journal Club 
December 2010 Pulmonary Journal Club

 

Both the Phoenix Good Samaritan/VA and the Tucson University of Arizona fellows previously had a periodic pulmonary journal club in which current or classic pulmonary articles were reviewed and discussed. A brief summary was written of each discussion describing thearticle and the strengths and weaknesses of each article.

-------------------------------------------------------------------------------------

Entries in chronic thromboembolic disease (1)

Monday
Jul292013

July 2013 Pulmonary Journal Club

Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C; CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319-32. [CrossRef] [PubMed]

Chronic Thromboembolic Disease (CTED) leading to pulmonary hypertension has an incidence of 5000 cases per year. It is estimated that up to 3% of all patients with pulmonary embolism develop CTED within 2 years of initial pulmonary embolism event.

The diagnosis of CTED is made through a ventilation perfusion scan detecting chronic thromboembolic disease. Treatment of CTED centers on anticoagulation and surgical thromboendartectomy. Thromboendartectomy is a unique procedure offered only in a few specialized centers throughout the country. Pharmacologic agents in the treatment of CTED have been ineffective except for bosentan. Bosentan, an endothelin receptor antagonist, has been shown to decrease pulmonary vascular resistance but not improve 6 minute walk time. Riociguat is a soluble guanylate cyclase stimulator, which works by increasing levels of cyclic GMP levels, resulting in vasorelaxation.

This study is a randomized double blind placebo controlled 16 week phase 3 trial evaluating the efficacy and safety of riociguat. The study was performed between 2009 – 2012 within 26 countries and 89 centers. A total of 261 patients were included in the study. Patients were excluded if they were pharmacologic agents used in the treatment of pulmonary hypertension. The primary outcome of the study was the improvement in 6 minute walk distance. Secondary outcomes included changes in pulmonary vascular resistance, N terminal BNP levels, WHO functional classification, Dyspnea severity. Medication side effect profiles were also noted.

Patients were divided into 2 groups, 88 subjects in the placebo group and 173 subjects in the treatment group. The discrepancy in sample size was based on needing 173 subjects within the treatment arm to reach a power of 90%. The dose of riociguat was adjusted between 0.5 mg to 2.5mg three times a day based on tolerance to side effects. This dose adjustment was done over the first 8 weeks and then a stable dose maintained for the next 8 weeks. At the end of the 16 weeks outcomes and safety profiles were measured.

The results showed that riociguat improved 6 minute walk distance by a mean of 39 meters as opposed to a decline of 6 meters within placebo. Secondary outcomes were also favorable showing an improvement in cardiac output while decreasing the pulmonary vascular resistance and pulmonary pressures.

The side effects included right ventricular failure in 3% and syncope in 2% of the subjects, both of which were the same in the placebo group. Two percent of patients stopped the drug due to nausea, vomiting and headache and another 2% developed hemoptysis. Two patients died in the treatment arm secondary to drug related heart failure and acute renal failure.

The study demonstrated that riociguat may offer benefit in patients ineligible for thromboendartectomy. Further studies to evaluate longitudinal benefits and safety profiles are needed.

Manoj Mathew, MD FCCP MCCM

Reference as: Mathew M. July 2013 pulmonary journal club. Southwest J Pulm Crit Care. 2013;7(1):51-2. doi: http://dx.doi.org/10.13175/swjpcc097-13 PDF